Robin Carhart-Harris

Overview

Robin Carhart-Harris is presented in the source as a UCSF professor of neurology and psychiatry and a leading researcher on psychedelic drugs, brain networks, and psychedelic-assisted therapy.

Current Profile

In The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris, Carhart-Harris links classic psychedelics’ serotonin 2A pharmacology with changes in subjective experience and whole-brain organization. He argues that therapeutic research must take the experience seriously: trust, willingness to let go, supported confrontation with difficult material, emotional release, insight, and subsequent integration may be parts of the intervention rather than noise around a drug effect.

His research profile is also strongly qualified. He describes increased global connectivity and reduced modularity during psychedelic states, and reports promising depression, anorexia, fibromyalgia, cognitive-flexibility, EEG, and imaging findings. At the same time, he labels microdosing evidence thin, distinguishes published from unpublished work, cautions against overextending network measures, acknowledges relapse, and emphasizes professional safeguards and legal constraints.

Key Characteristics

• Connects psychedelic pharmacology, subjective experience, psychotherapy, and brain-network imaging.
• Treats “trust, let go, be open” as a clinical-process hypothesis rather than a universal self-use instruction.
• Distinguishes classic psychedelics from MDMA, ketamine, cannabis, and non-hallucinogenic serotonin 2A drug development.
• Uses global connectivity and modularity as candidate correlates while warning against simple causal interpretation.
• Reports promising clinical signals alongside explicit publication, replication, durability, and access limits.
• Supports regulated, trained, professionally safeguarded care rather than general recreational or unsupervised use.

Evidence

• Therapy-process account - The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris links rapport, surrender, openness, music, guides, difficult experience, and integration to the therapeutic model.
• Network research - The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris describes increased global connectivity, reduced modularity, EEG complexity, and qualified structural-imaging findings.
• Evidence calibration - The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris marks microdosing evidence as thin and several anorexia, fibromyalgia, and healthy-volunteer findings as early or unpublished.
• Safety and durability - The Science of Psychedelics for Mental Health | Dr. Robin Carhart-Harris discusses relapse, restricted post-trial access, practitioner standards, boundary violations, contamination, and emergency support.

Qualifications

This profile is bounded to one May 2023 interview summary, not Carhart-Harris’s full publication record or current institutional role. Reported affiliations, trial status, regulatory forecasts, percentages, imaging results, and condition-specific outcomes are historical and source-scoped. The page does not establish clinical efficacy, legal access, individual eligibility, or safe self-administration.

What Changed

• Created a source-bounded profile connecting Carhart-Harris’s therapeutic-process, network-neuroscience, evidence-calibration, and safety views.

Relationships

• Andrew Huberman - interviewer who elicits the clinical, neuroscience, and safety framework.
• Psychedelic Therapy Mechanism - central combined biological and experiential model discussed in the interview.
• Brain Network Modularity - network statistic Carhart-Harris uses to describe psychedelic state change.
• Psychedelic Integration - post-session process he treats as potentially lifelong practice.
• Psychedelic Clinical Supervision Boundary - evidence and safety rule reinforced throughout the interview.
• MDMA-Assisted PTSD Therapy - adjacent therapy model he contrasts with classic psychedelic sessions.